Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening

Journal of Chemical Information and Modeling

Volumn 54, Issue 11, 2014, Pages 3046-3050

  Wang, Yan ^a   Law, Wai Kit ^a   Hu, Jian Shu ^a   Lin, Huang Quan ^b   Ip, Tsz Ming ^a   Wan, David Chi Cheong ^a  

^a Prince of Wales Hospital   (Hong Kong)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MODELING; PROTEINS;

ADIPOGENESIS; ADVERSE EFFECT; BIOCHEMICAL CHARACTERIZATION; CHEMICAL EQUATIONS; FATTY ACID-BINDING PROTEINS; LEVOFLOXACIN; LIGAND DISPLACEMENT; MOLECULAR DOCKING;

FATTY ACIDS;

FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; LIGAND; MOLECULAR LIBRARY;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG APPROVAL; DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; METABOLIC DISEASES; METABOLISM; MOLECULAR DOCKING; MOLECULAR LIBRARY; PHARMACOLOGY; PROTEIN CONFORMATION; THERAPEUTIC USE; UNITED STATES;

DRUG APPROVAL; DRUG DISCOVERY; FATTY ACID-BINDING PROTEINS; HUMANS; LIGANDS; METABOLIC DISEASES; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; SMALL MOLECULE LIBRARIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84912574999     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci500503b     Document Type: Article

References (35)

1. Boden, G. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol., Diabetes Obes. 2011, 18, 139-143.
2. Karpe, F.; Dickmann, J. R.; Frayn, K. N. Fatty acids, obesity, and insulin resistance: Time for a reevaluation. Diabetes 2011, 60, 2441-2449.
3. Smit, E. N.; Muskiet, F. A.; Boersma, E. R. The possible role of essential fatty acids in the pathophysiology of malnutrition: A review. Prostaglandins, Leukotrienes Essent. Fatty Acids 2004, 71, 241-250.
4. Boord, J. B.; Fazio, S.; Linton, M. F. Cytoplasmic fatty acid-binding proteins: Emerging roles in metabolism and atherosclerosis. Curr. Opin. Lipidol. 2002, 13, 141-147.
5. Furuhashi, M.; Hotamisligil, G. S. Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discovery 2008, 7, 489-503.
6. Furuhashi, M.; Tuncman, G.; Gorgun, C. Z.; Makowski, L.; Atsumi, G.; Vaillancourt, E.; Kono, K.; Babaev, V. R.; Fazio, S.; Linton, M. F.; Sulsky, R.; Robl, J. A.; Parker, R. A.; Hotamisligil, G. S. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein Ap2. Nature 2007, 447, 959-965.
7. Lehmann, F.; Haile, S.; Axen, E.; Medina, C.; Uppenberg, J.; Svensson, S.; Lundback, T.; Rondahl, L.; Barf, T. Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg. Med. Chem. Lett. 2004, 14, 4445-4448.
8. Adida, A.; Spener, F. Adipocyte-type fatty acid-binding protein as inter-compartmental shuttle for peroxisome proliferator activated receptor gamma agonists in cultured cell. Biochim. Biophys. Acta 2006, 1761, 172-181.
9. Garin-Shkolnik, T.; Rudich, A.; Hotamisligil, G. S.; Rubinstein, M. Fabp4 attenuates ppargamma and adipogenesis and is inversely correlated with ppargamma in adipose tissues. Diabetes 2014, 63, 900-911.
10. Ahmadian, M.; Suh, J. M.; Hah, N.; Liddle, C.; Atkins, A. R.; Downes, M.; Evans, R. M. Ppargamma signaling and metabolism: The good, the bad and the future. Nat. Med. 2013, 19, 557-566.
11. Leung, C. H.; Chan, D. S.; Kwan, M. H.; Cheng, Z.; Wong, C. Y.; Zhu, G. Y.; Fong, W. F.; Ma, D. L. Structure-based repurposing of FDA-Approved Drugs as Tnf-alpha inhibitors. ChemMedChem. 2011, 6, 765-768.
12. Ma, D. L.; Chan, D. S.; Leung, C. H. Drug repositioning by structure-based virtual screening. Chem. Soc. Rev. 2013, 42, 2130-2141.
13. Zhong, H. J.; Liu, L. J.; Chan, D. S.; Wang, H. M.; Chan, P. W.; Ma, D. L.; Leung, C. H. Structure-based repurposing of FDA-approved drugs as inhibitors of Nedd8-activating enzyme. Biochimie 2014, 102, 211-215.
14. Bisson, W. H. Drug repurposing in chemical genomics: Can we learn from the past to improve the future? Curr. Top Med. Chem. 2012, 12, 1883-1888.
15. Ng, C.; Hauptman, R.; Zhang, Y.; Bourne, P. E.; Xie, L. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems biology approach. Pac. Symp. Biocomput. 2014, 136-147.
16. Oprea, T. I.; Mestres, J. Drug repurposing: Far beyond new targets for old drugs. AAPS J. 2012, 14, 759-763.
17. Eberhard, Y.; McDermott, S. P.; Wang, X.; Gronda, M.; Venugopal, A.; Wood, T. E.; Hurren, R.; Datti, A.; Batey, R. A.; Wrana, J.; Antholine, W. E.; Dick, J. E.; Schimmer, A. D. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009, 114, 3064-3073.
18. Minden, M. D.; Hogge, D. E.; Weir, S. J.; Kasper, J.; Webster, D. A.; Patton, L.; Jitkova, Y.; Hurren, R.; Gronda, M.; Goard, C. A.; Rajewski, L. G.; Haslam, J. L.; Heppert, K. E.; Schorno, K.; Chang, H.; Brandwein, J. M.; Gupta, V.; Schuh, A. C.; Trudel, S.; Yee, K. W.; Reed, G. A.; Schimmer, A. D. Oral ciclopirox olamine displays biological activity in a phase i study in patients with advanced hematologic malignancies. Am. J. Hematol 2014, 89, 363-368.
19. Ringom, R.; Axen, E.; Uppenberg, J.; Lundback, T.; Rondahl, L.; Barf, T. Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1h)-ones: A novel class of selective human a-Fabp inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 4449-4452.
20. Sulsky, R.; Magnin, D. R.; Huang, Y.; Simpkins, L.; Taunk, P.; Patel, M.; Zhu, Y.; Stouch, T. R.; Bassolino-Klimas, D.; Parker, R.; Harrity, T.; Stoffel, R.; Taylor, D. S.; Lavoie, T. B.; Kish, K.; Jacobson, B. L.; Sheriff, S.; Adam, L. P.; Ewing, W. R.; Robl, J. A. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (Afabp). Bioorg. Med. Chem. Lett. 2007, 17, 3511-3515.
21. Barf, T.; Lehmann, F.; Hammer, K.; Haile, S.; Axen, E.; Medina, C.; Uppenberg, J.; Svensson, S.; Rondahl, L.; Lundback, T. N-Benzylindolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (a-Fabp) inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 1745-1748.
22. Ha, S. O.; Kim, D. Y.; Sohn, C. H.; Lim, K. S. Anaphylaxis caused by intravenous fluorescein: Clinical characteristics and review of literature. Intern. Emerg. Med. 2014, 9, 325-330.
23. Charleston, L. t. Burning mouth syndrome: A review of recent literature. Curr. Pain Headache Rep. 2013, 17, 336.
24. Leatham, P. A.; Bird, H. A.; Wright, V.; Seymour, D.; Gordon, A. A double blind study of antrafenine, naproxen and placebo in osteoarthrosis. Eur. J. Rheumatol. Inflammation 1983, 6, 209-211.
25. Bak, M.; Fransen, A.; Janssen, J.; van Os, J.; Drukker, M. Almost all antipsychotics result in weight gain: A meta-analysis. PLoS One 2014, 9, e94112.
26. Goldstein, E. J. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and Du-6859a) in the treatment of anaerobic infections: Review of current information on efficacy and safety. Clin. Infect. Dis. 1996, 23 (Suppl 1), S25-S30.
27. Davis, R.; Bryson, H. M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994, 47, 677-700.
28. Wimer, S. M.; Schoonover, L.; Garrison, M. W. Levofloxacin: A therapeutic review. Clin. Ther. 1998, 20, 1049-1070.
29. Dudley, M. N.; Tsivkovski, R. Y.; Griffith, D. C.; Rodny, O. Topical Use of Levo floxacin for Reducing Lung Inflammation. U. S. Patent US20100087386 A1, 2010.
30. Gillilan, R. E.; Ayers, S. D.; Noy, N. Structural basis for activation of fatty acid-binding protein 4. J. Mol. Biol. 2007, 372, 1246-1260.
31. Cai, H. Y.; Wang, T.; Zhao, J. C.; Sun, P.; Yan, G. R.; Ding, H. P.; Li, Y. X.; Wang, H. Y.; Zhu, W. L.; Chen, K. X. Benzbromarone, an old uricosuric drug, inhibits human fatty acid binding protein 4 in vitro and lowers the blood glucose level in Db/Db mice. Acta Pharmacol. Sin. 2013, 34, 1397-1402.
32. Maeda, K.; Cao, H.; Kono, K.; Gorgun, C. Z.; Furuhashi, M.; Uysal, K. T.; Cao, Q.; Atsumi, G.; Malone, H.; Krishnan, B.; Minokoshi, Y.; Kahn, B. B.; Parker, R. A.; Hotamisligil, G. S. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 2005, 1, 107-119.
33. Friedrich, L. V.; Dougherty, R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004, 24, 1807-1812.
34. Kanbay, M.; Aydogan, T.; Bozalan, R.; Isik, A.; Uz, B.; Kaya, A.; Akcay, A. A rare but serious side effect of levofloxacin: Hypoglycemia in a geriatric patient. Diabetes Care 2006, 29, 1716-1717.
35. Singh, N.; Jacob, J. J. Levofloxacin and hypoglycemia. Clin. Infect. Dis. 2008, 46, 1127.